Summary

Dermatological Therapeutics Market Size
The global dermatological therapeuticsmarket size was valued at $52.07 billion in 2025 and is projected to reach $100.05 billion by 2031, growing at a CAGR of 11.5% during the forecast period.

Dermatological Therapeutics Market Overview
Dermatological therapeutics is a rapidly growing field that focuses on the treatment of various skin conditions, including acne, psoriasis, eczema, and skin cancer. The global dermatological therapeutics market has been expanding due to factors such as increased prevalence of skin diseases, rising awareness about skin health, and advancements in treatment options.
Companies in the dermatological therapeutics market can benefit in several ways. Firstly, the increasing demand for effective treatments presents opportunities for pharmaceutical and biotechnology companies to develop and market innovative drugs and therapies. Secondly, the aging population and growing focus on skincare create a larger target audience for dermatological products. Additionally, collaborations between companies and dermatologists can lead to the development of specialized products tailored to specific skin conditions. Furthermore, companies can leverage digital channels to expand their reach and connect with a wider customer base. With the market projected to continue growing, companies that invest in research and development, maintain high-quality standards, and effectively market their products are well-positioned to capitalize on the opportunities in the dermatological therapeutics market.

Dermatological Therapeutics Market Dynamics
The dermatological therapeuticsmarket is expected to witness significant growth in the future due to the increasing prevalence of skin diseases, growing elderly population, and advancements in therapeutic solutions. However, the serious side effects, governmental regulations and guidelines, and patent expiration are restraining the growth of the market.

Furthermore, increasing demand for effective and affordable treatments, growing popularity of over-the-counter (OTC) medications, and surge in R&D spending are the key trends propelling the dermatological therapeuticsmarket.

Increasing Prevalence of Skin Diseasesis Driving the Dermatological Therapeutics Market
The increasing prevalence of skin diseases is significantly impacting the dermatological therapeuticsmarket, by driving demand for effective treatments and development innovation among pharmaceutical companies.
• For instance, the American Academy of Dermatology reported that over 84.5 million people in the U.S. are affected by skin diseases, with acne being the most common condition. This high prevalence has led to a surge in the development of specialized drugs, particularly biologics, which target chronic conditions such as psoriasis and eczema.
• Companies like AbbVie and Janssen Biotech have been at the forefront, investing in research and launching innovative treatments that cater to these needs.
• In 2022, the U.S. FDA approved 37 new dermatological drugs, reflecting a growing focus on addressing skin disorders.
• Notably, in May 2020, Sanofi received FDA approval for Dupixent, aimed at treating atopic dermatitis in children aged 6 to 11, highlighting the ongoing commitment to developing targeted therapies for vulnerable populations.
• Furthermore, the World Health Organization has identified skin disorders as one of the top ten causes of disability, affecting around 900 million people globally, which underscores the urgent need for effective dermatological solutions.
The market is also benefiting from governmental initiatives aimed at improving access to dermatological care.
• For example, increased healthcare expenditure in North America is facilitating the development and distribution of dermatological therapeutics.
In the Asia Pacific region, countries like China and India are witnessing improvements in access to skin care treatments, further propelling market growth as awareness about skin diseases rises. The combination of these factors illustrates how the growing incidence of skin diseases is not only enhancing market opportunities but also driving innovation and investment in dermatological therapeutics.

By Application, the PsoriasisSegment is projected to be the Largest Segment in the Dermatological Therapeutics Market
Psoriasis is the largest segment in the dermatological therapeuticsmarket, driven by the rising prevalence of the disease, advancements in treatment options, and ongoing clinical research.
• According to the National Psoriasis Foundation, as of December 2022, approximately 125 million people globally suffer from psoriasis, which accounts for 2-3% of the total population. In the United States alone, over 8 million individuals are affected, highlighting the substantial market potential for psoriasis treatments.
To address this growing need, pharmaceutical companies are actively developing new therapies.
• For example, in September 2022, the FDA approved Sotyktu (deucravacitinib), an oral treatment specifically for adults with moderate-to-severe plaque psoriasis, marking a significant advancement in therapeutic options.
• Similarly, in July 2022, the FDA approved ZORYVE (roflumilast cream) for the treatment of plaque psoriasis in patients aged 12 and older, further expanding the available treatment landscape.
• Moreover, the increasing number of clinical trials is indicative of the ongoing commitment to psoriasis research. As of February 2023, there were approximately 325 ongoing clinical trials focused on psoriasis treatments, suggesting a robust pipeline of potential new therapies that could enhance patient outcomes. This focus on innovation is supported by major companies such as Amgen, AbbVie, and Novartis, which are investing heavily in research and development to bring new and effective treatments to market.
Government initiatives also play a crucial role in fostering this demand.
• For instance, healthcare policies aimed at improving access to dermatological care are essential, especially for patients in underserved regions.
The combination of these factors, high disease prevalence, innovative product launches, and supportive clinical research—positions the psoriasis segment of the dermatological therapeutics market for continued growth in the coming years.

By Geography, North America Holds the Largest Share in the Market Revenue
North American region holds the largest share of the dermatological therapeuticsmarket, driven by a high prevalence of skin diseases, increasing healthcare expenditure, and a robust pipeline of innovative products.
• According to the National Psoriasis Foundation, over 8 million Americans suffer from psoriasis, a condition that significantly impacts quality of life and necessitates effective treatment options. This has prompted pharmaceutical companies to invest heavily in research and development.
• For instance, in July 2021, Sol-Gel Technologies received FDA approval for TWYNEO (tretinoin/benzoyl peroxide) cream, aimed at treating acne vulgaris, while in September 2021, Incyte launched Opzelura (ruxolitinib) cream for atopic dermatitis, showcasing the commitment to addressing prevalent skin conditions.
Additionally, the aging population in North America contributes to the increasing demand for dermatological care, as older adults are more susceptible to skin disorders. Statistics Canada indicated that as of July 2022, approximately 18.8% of the Canadian population was aged 65 and older, further underscoring the need for effective dermatological treatments tailored to this demographic. Government initiatives aimed at improving healthcare access and awareness about skin diseases also play a crucial role in driving market growth.

Key Target Audience:
• Pharmaceutical Companies
• Biotechnology Firms
• Healthcare Providers
• Patients
• Regulatory Bodies
• Insurance Companies

List of the Key Players Profiled in the Report Includes:
• Allergen plc
• Novartis
• Sanofi
• Dermira
• Pfizer Inc.
• GlaxoSmithKline Plc.
• Foamix Pharmaceutical
• Sun Pharmaceutical
• Mayne Pharma
• Glenmark Pharmaceutical
• Valeant Pharmaceuticals
• Galderma SA

Recent Developments:
• In September 2023, Mayne Pharma announced the launch of a new generic version of a popular acne treatment, expanding its presence in the dermatological market.
• In August 2023, Sun Pharmaceutical announced the launch of a new topical formulation for the treatment of psoriasis, which aims to provide patients with more effective management options.
• In June 2023, GSK announced the launch of its new topical treatment, Duobrii (halobetasol propionate and tazarotene), for the treatment of plaque psoriasis, expanding its offerings in dermatological therapies.

Market Segmentation:
The research report includes in-depth coverage of the industry analysis with size, share, and forecast for the below segments:

Market by, Drug Class:
• Anti-acne
• Anti-infectives
• Calcineurin Inhibitors
• Corticosteroids
• Retinoids
• Other Drug Classes

Market by, Application:
• Acne vulgaris
• Alopecia
• Atopic Dermatitis
• Herpes
• Psoriasis
• Rosacea
• Other Applications

Market by, Geography:
The dermatological therapeuticsmarket report also analyzes the major geographic regions and countries of the market. The regions and countries covered in the study include:
• North America (The United States, Canada, Mexico), Market Estimates, Forecast & Opportunity Analysis
• Europe (Germany, France, UK, Italy, Spain, Rest of Europe), Market Estimates, Forecast & Opportunity Analysis
• Asia Pacific (China, Japan, India, South Korea, Australia, New Zealand, Rest of Asia Pacific), Market Estimates, Forecast & Opportunity Analysis
• South America (Brazil, Argentina, Chile, Rest of South America), Market Estimates, Forecast & Opportunity Analysis
• Middle East & Africa (UAE, Saudi Arabia, Qatar, Iran, South Africa, Rest of Middle East & Africa), Market Estimates, Forecast & Opportunity Analysis

The report offers insights into the following aspects:
• Analysis of major market trends, factors driving, restraining, threatening, and providing opportunities for the market.
• Analysis of the market structure by identifying various segments and sub-segments of the market.
• Understand the revenue forecast of the market for North America, Europe, Asia-Pacific, South America, and Middle East & Africa.
• Analysis of opportunities by identification of high-growth segments/revenue pockets in the market.
• Understand major player profiles in the market and analyze their business strategies.
• Understand competitive developments such as joint ventures, alliances, mergers and acquisitions, and new product launches in the market.

ページTOPに戻る

Table of Contents

1 Market Introduction
1.1 Market Definition
1.2 Research Scope and Segmentation
1.3 Stakeholders
1.4 List of Abbreviations

2 Executive Summary

3 Research Methodology
3.1 Identification of Data
3.2 Data Analysis
3.3 Verification
3.4 Data Sources
3.5 Assumptions

4 Market Dynamics
4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5 Porter's Five Force Analysis
5.1 Bargaining Power of Suppliers
5.2 Bargaining Power of Buyers
5.3 Threat of New Entrants
5.4 Threat of Substitutes
5.5 Competitive Rivalry in the Market

6 Global Dermatological Therapeutics Market by, Drug Class
6.1 Overview
6.2 Anti-acne
6.3 Anti-infectives
6.4 Calcineurin Inhibitors
6.5 Corticosteroids
6.6 Retinoids
6.7 Other Drug Classes

7 Global Dermatological Therapeutics Market by, Application
7.1 Overview
7.2 Acne vulgaris
7.3 Alopecia
7.4 Atopic Dermatitis
7.5 Herpes
7.6 Psoriasis
7.7 Rosacea
7.8 Other Applications

8 Global Dermatological Therapeutics Market by, Geography
8.1 Overview
8.2 North America
8.2.1 US
8.2.2 Canada
8.2.3 Mexico
8.3 Europe
8.3.1 Germany
8.3.2 France
8.3.3 UK
8.3.4 Italy
8.3.5 Spain
8.3.6 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 South Korea
8.4.5 Australia
8.4.6 New Zealand
8.4.7 Rest of Asia Pacific
8.5 South America
8.5.1 Brazil
8.5.2 Argentina
8.5.3 Chile
8.5.4 Rest of South America
8.6 Middle East & Africa
8.6.1 UAE
8.6.2 Saudi Arabia
8.6.3 Qatar
8.6.4 Iran
8.6.5 South Africa
8.6.6 Rest of Middle East & Africa

9 Key Developments

10 Company Profiling
10.1 Allergen plc
10.1.1 Business Overview
10.1.2 Product/Service Offering
10.1.3 Financial Overview
10.1.4 SWOT Analysis
10.1.5 Key Activities
10.2 Novartis
10.3 Sanofi
10.4 Dermira
10.5 Pfizer Inc.
10.6 GlaxoSmithKline Plc.
10.7 Foamix Pharmaceutical
10.8 Sun Pharmaceutical
10.9 Mayne Pharma
10.10 Glenmark Pharmaceutical
10.11 Valeant Pharmaceuticals
10.12 Galderma SA